NAT1: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of NAT1. The page also collects GeneMedi's different modalities and formats products for NAT1 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the NAT1 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Introcelluar Protein.

This gene is one of two arylamine N-acetyltransferase (NAT) genes in the human genome, and is orthologous to the mouse and rat Nat2 genes. The enzyme encoded by this gene catalyzes the transfer of an acetyl group from acetyl-CoA to various arylamine and hydrazine substrates. This enzyme helps metabolize drugs and other xenobiotics, and functions in folate catabolism. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2011]

Target IDGM-TA048
Target NameNAT1
Gene ID9,17960,704019
Gene Symbol and SynonymsAAC1,MNAT,NAT-1,NAT1,NATI
Uniprot AccessionP18440
Uniprot Entry NameARY1_HUMAN
Protein Sub-locationIntrocelluar Protein
CategoryTherapeutics Target
DiseaseBreast Cancer
Gene EnsemblENSG00000171428
Target ClassificationN/A


Pre-made anti-NAT1 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-NAT1 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-NAT1 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Antibody NameSpeciesFormatClassified by tagDetail
Anti-NAT1 monoclonal antibodyHuman, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquinemabTherapeutics Target antibodyDetail



Recombinant multi-species ARY1/ NAT1/ AAC1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine NAT1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

Products NameSpeciesExpression PlatformDetail
NAT1 proteinHuman, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquineMammalian cellDetail



Pre-made NAT1 viral vector in GM Promise-ORFTM

Cat No.Products nameNM IDSpeciesTypeDetail
pGMLP003332human NAT1 Lentivirus plasmidNM_000662HumanLentivirus plasmidDetail
vGMLP003332human NAT1 Lentivirus particleNM_000662HumanLentivirus particleDetail
pGMLPm002588mouse Nat1 Lentivirus plasmidNM_008673MouseLentivirus plasmidDetail
vGMLPm002588mouse Nat1 Lentivirus particleNM_008673MouseLentivirus particleDetail

About Promise-ORFTM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORFTM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORFTM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI

If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.